USFDA issues Form 483 with five inspectional observations to Marksans Pharma#39;s Goa unit

The US Food and Drug Administration (USFDA) had conducted a routine current Good Manufacturing Practices (cGMP) inspection at the manufacturing facility from April 9-17, 2024, the company said in a regulatory filing.

from Moneycontrol Business News https://ift.tt/pB1LykM